CoChat
Sign Up
Cited by 278Gut microbiota and healthAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored

Open access
Chandra, Sidhanth, Sisodia, Sangram S., Vassar, Robert J.·2023·Molecular Neurodegeneration
DOI 10.1186/s13024-023-00595-7PMC PMC9889249
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD), the most common cause of dementia, results in a sustained decline in cognition. There are currently few effective disease modifying therapies for AD, but insights into the mechanisms that mediate the onset and progression of disease may lead to new, effective therapeutic strategies. Amyloid beta oligomers and plaques, tau aggregates, and neuroinflammation play a critical role in neurodegeneration and impact clinical AD progression. The upstream modulators of these pathological features have not been fully clarified, but recent evidence indicates that the gut microbiome (GMB) may have an influence on these features and therefore may influence AD progression in human patients. In this review, we summarize studies that have identified alterations in the GMB that correlate with pathophysiology in AD patients and AD mouse models. Additionally, we discuss findings with GMB manipulations in AD models and potential GMB-targeted therapeutics for AD. Lastly, we discuss diet, sleep, and exercise as potential modifiers of the relationship between the GMB and AD and conclude with future directions and recommendations for further studies of this topic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-023-00595-7

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Theory of GMB involvement in AD. Environmental factors, such as diet, sleep, and exercise and the development of AD due to genetics contribute to an inflammatory environment in the gut microbiota, which leads to changes in composition and diversity over time. Changes in the gut microbiota influence gut microbiome-derived metabolites and peripheral immunity by altering peripheral immune cell gene expression and cytokine release. Changes in peripheral immunity, possibly gut-derived metabolites directly, and vagus nerve trafficked gut-derived hormones can then alter phenotype of the blood brain barrier and central nervous system cell types (microglia, astrocytes, neurons), which can then modulate amyloidosis, tauopathy, and neurodegeneration and contribute to disease pathogenesis
Fig. 1 Theory of GMB involvement in AD. Environmental factors, such as diet, sleep, and exercise and the development of AD due to genetics contribute to an inflammatory environment in the gut microbiota, which leads to changes in composition and diversity over time. Changes in the gut microbiota influence gut microbiome-derived metabolites and peripheral immunity by altering peripheral immune cell gene expression and cytokine release. Changes in peripheral immunity, possibly gut-derived metabolites directly, and vagus nerve trafficked gut-derived hormones can then alter phenotype of the blood brain barrier and central nervous system cell types (microglia, astrocytes, neurons), which can then modulate amyloidosis, tauopathy, and neurodegeneration and contribute to disease pathogenesisCC BY · PubMed Central
Fig. 2 Microbiome-related therapeutic strategies for AD. Preliminary evidence from mouse and human studies suggests that probiotics/prebiotics, fecal matter transplant from healthy donors into AD patients, microbiome modifying drugs, and direct targeting of gut microbiome controlled neuroinflammatory pathways may potentially be disease modifying therapeutic strategies and may reduce amyloid, tau, and neurodegeneration
Fig. 2 Microbiome-related therapeutic strategies for AD. Preliminary evidence from mouse and human studies suggests that probiotics/prebiotics, fecal matter transplant from healthy donors into AD patients, microbiome modifying drugs, and direct targeting of gut microbiome controlled neuroinflammatory pathways may potentially be disease modifying therapeutic strategies and may reduce amyloid, tau, and neurodegenerationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–228 of 228

Cited by

Sorted by citations

See all 278

Related

See all

Metadata

Authors
Chandra, S., Sisodia, S. S., & Vassar, R. J.
Affiliations
  • Northwestern University (US)
  • University of Chicago (US)
Corresponding author
Vassar, Robert J.
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2023-02-01
Volume
18
Issue
1
Pages
9-9
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-023-00595-7
PMC
PMC9889249
OpenAlex
W4318680477
Cited by
278
References
228
Citations by year
2026: 56 · 2025: 100 · 2024: 84 · 2023: 38
FWCI
7.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Chicago (cc-by)
Funders
Good ventures foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, gut microbiota, amyloid-beta, tau aggregates, neuroinflammation, neurodegeneration, gut-brain axis, microbiota-based therapy, diet, sleep, physical activity, mouse models of Alzheimer's disease
MeSH terms
Gastrointestinal Microbiome, Alzheimer Disease, Animals, Cognition, Disease Models, Animal, Humans, Amyloid beta-Peptides, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review